Browse GRIN3A

Summary
SymbolGRIN3A
Nameglutamate receptor, ionotropic, N-methyl-D-aspartate 3A
Aliases GluN3A; NMDAR-L; NR3A; N-methyl-D-aspartate receptor subtype 3A; NMDAR3A; glutamate [NMDA] receptor subunit ......
Chromosomal Location9q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Multi-pass membrane protein Cell junction, synapse, postsynaptic cell membrane Cell junction, synapse, postsynaptic cell membrane, postsynaptic density Note=Enriched in postsynaptic plasma membrane and postsynaptic densities. Requires the presence of GRIN1 to be targeted at the plasma membrane (By similarity).
Domain PF00060 Ligand-gated ion channel
PF10613 Ligated ion channel L-glutamate- and glycine-binding site
Function

NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine. May play a role in the development of dendritic spines. May play a role in PPP2CB-NMDAR mediated signaling mechanism (By similarity).

> Gene Ontology
 
Biological Process GO:0001964 startle response
GO:0006816 calcium ion transport
GO:0007215 glutamate receptor signaling pathway
GO:0016358 dendrite development
GO:0032102 negative regulation of response to external stimulus
GO:0035235 ionotropic glutamate receptor signaling pathway
GO:0045471 response to ethanol
GO:0050905 neuromuscular process
GO:0060134 prepulse inhibition
GO:0070588 calcium ion transmembrane transport
GO:0070838 divalent metal ion transport
GO:0072511 divalent inorganic cation transport
GO:0097305 response to alcohol
Molecular Function GO:0004970 ionotropic glutamate receptor activity
GO:0004972 NMDA glutamate receptor activity
GO:0005216 ion channel activity
GO:0005230 extracellular ligand-gated ion channel activity
GO:0005231 excitatory extracellular ligand-gated ion channel activity
GO:0005234 extracellular-glutamate-gated ion channel activity
GO:0005261 cation channel activity
GO:0005262 calcium channel activity
GO:0008066 glutamate receptor activity
GO:0015085 calcium ion transmembrane transporter activity
GO:0015267 channel activity
GO:0015276 ligand-gated ion channel activity
GO:0016594 glycine binding
GO:0016597 amino acid binding
GO:0019902 phosphatase binding
GO:0019903 protein phosphatase binding
GO:0022803 passive transmembrane transporter activity
GO:0022824 transmitter-gated ion channel activity
GO:0022834 ligand-gated channel activity
GO:0022835 transmitter-gated channel activity
GO:0022836 gated channel activity
GO:0022838 substrate-specific channel activity
GO:0030594 neurotransmitter receptor activity
GO:0031406 carboxylic acid binding
GO:0043168 anion binding
GO:0046873 metal ion transmembrane transporter activity
GO:0051721 protein phosphatase 2A binding
GO:0072509 divalent inorganic cation transmembrane transporter activity
Cellular Component GO:0008328 ionotropic glutamate receptor complex
GO:0014069 postsynaptic density
GO:0017146 NMDA selective glutamate receptor complex
GO:0034702 ion channel complex
GO:0043025 neuronal cell body
GO:0043235 receptor complex
GO:0044297 cell body
GO:0045211 postsynaptic membrane
GO:0060076 excitatory synapse
GO:0097060 synaptic membrane
GO:0098794 postsynapse
GO:0098802 plasma membrane receptor complex
GO:0098878 neurotransmitter receptor complex
GO:0099572 postsynaptic specialization
GO:1902495 transmembrane transporter complex
GO:1990351 transporter complex
> KEGG and Reactome Pathway
 
KEGG hsa04024 cAMP signaling pathway
hsa04080 Neuroactive ligand-receptor interaction
hsa04724 Glutamatergic synapse
Reactome -
Summary
SymbolGRIN3A
Nameglutamate receptor, ionotropic, N-methyl-D-aspartate 3A
Aliases GluN3A; NMDAR-L; NR3A; N-methyl-D-aspartate receptor subtype 3A; NMDAR3A; glutamate [NMDA] receptor subunit ......
Chromosomal Location9q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between GRIN3A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolGRIN3A
Nameglutamate receptor, ionotropic, N-methyl-D-aspartate 3A
Aliases GluN3A; NMDAR-L; NR3A; N-methyl-D-aspartate receptor subtype 3A; NMDAR3A; glutamate [NMDA] receptor subunit ......
Chromosomal Location9q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of GRIN3A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolGRIN3A
Nameglutamate receptor, ionotropic, N-methyl-D-aspartate 3A
Aliases GluN3A; NMDAR-L; NR3A; N-methyl-D-aspartate receptor subtype 3A; NMDAR3A; glutamate [NMDA] receptor subunit ......
Chromosomal Location9q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of GRIN3A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1970.659
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.7630.526
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5080.693
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.7050.0418
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.9890.0836
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3580.572
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3830.294
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.3690.457
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.6720.0175
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of GRIN3A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.15.55.60.384
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.16.84.30.673
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211728.635.3-6.70.734
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131138.554.5-160.682
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.17.71.41
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolGRIN3A
Nameglutamate receptor, ionotropic, N-methyl-D-aspartate 3A
Aliases GluN3A; NMDAR-L; NR3A; N-methyl-D-aspartate receptor subtype 3A; NMDAR3A; glutamate [NMDA] receptor subunit ......
Chromosomal Location9q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GRIN3A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolGRIN3A
Nameglutamate receptor, ionotropic, N-methyl-D-aspartate 3A
Aliases GluN3A; NMDAR-L; NR3A; N-methyl-D-aspartate receptor subtype 3A; NMDAR3A; glutamate [NMDA] receptor subunit ......
Chromosomal Location9q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GRIN3A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GRIN3A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolGRIN3A
Nameglutamate receptor, ionotropic, N-methyl-D-aspartate 3A
Aliases GluN3A; NMDAR-L; NR3A; N-methyl-D-aspartate receptor subtype 3A; NMDAR3A; glutamate [NMDA] receptor subunit ......
Chromosomal Location9q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GRIN3A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolGRIN3A
Nameglutamate receptor, ionotropic, N-methyl-D-aspartate 3A
Aliases GluN3A; NMDAR-L; NR3A; N-methyl-D-aspartate receptor subtype 3A; NMDAR3A; glutamate [NMDA] receptor subunit ......
Chromosomal Location9q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of GRIN3A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolGRIN3A
Nameglutamate receptor, ionotropic, N-methyl-D-aspartate 3A
Aliases GluN3A; NMDAR-L; NR3A; N-methyl-D-aspartate receptor subtype 3A; NMDAR3A; glutamate [NMDA] receptor subunit ......
Chromosomal Location9q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between GRIN3A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolGRIN3A
Nameglutamate receptor, ionotropic, N-methyl-D-aspartate 3A
Aliases GluN3A; NMDAR-L; NR3A; N-methyl-D-aspartate receptor subtype 3A; NMDAR3A; glutamate [NMDA] receptor subunit ......
Chromosomal Location9q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting GRIN3A collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting GRIN3A.
ID Name Drug Type Targets #Targets
DB00142Glutamic AcidSmall MoleculeAADAT, AASS, ABAT, ALDH18A1, ASNS, BCAT1, BCAT2, CCBL2, CPQ, DNPEP ......69
DB00193TramadolSmall MoleculeCHRM3, GRIN3A, HTR2C, OPRD1, OPRK1, OPRM1, SLC6A2, SLC6A48
DB00289AtomoxetineSmall MoleculeGRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, SLC6A2, SLC ......10
DB00312PentobarbitalSmall MoleculeCHRNA4, CHRNA7, GABRA1, GABRA1, GABRA2, GABRA2, GABRA3, GABRA3, GA ......34
DB00333MethadoneSmall MoleculeCHRNA10, GRIN3A, HTR3A, LY96, OPRD1, OPRM1, ORM27
DB00392EthopropazineSmall MoleculeCHRM1, CHRM2, GRIN3A3
DB00418SecobarbitalSmall MoleculeCHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GR ......17
DB00514DextromethorphanSmall MoleculeCHRNA2, CHRNA3, CHRNA4, CHRNA7, CHRNB2, CHRNB4, CYBA, CYBB, GRIN3A ......21
DB00659AcamprosateSmall MoleculeGABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GA ......24
DB00721ProcaineSmall MoleculeCHRNA2, GRIN3A, HTR3A, KCNMA1, KCNMB1, KCNMB2, KCNMB3, KCNMB4, KCN ......16
DB00898EthanolSmall MoleculeCACNA1C, CACNA1D, CACNA1S, CACNB1, CACNG1, CACNG2, CHRNA10, CHRNA2 ......52
DB00915AmantadineSmall MoleculeDRD2, GRIN3A2
DB00949FelbamateSmall MoleculeGRIN2A, GRIN2B, GRIN3A3
DB00996GabapentinSmall MoleculeADORA1, CACNA1B, CACNA2D1, CACNA2D2, GABBR1, GABBR2, GRIN1, GRIN2A ......13
DB01043MemantineSmall MoleculeDRD2, GRIN1, GRIN2A, GRIN2B, GRIN3A, HTR3A6
DB01159HalothaneSmall MoleculeATP2C1, ATP5D, GABRA1, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GAB ......33
DB01161ChloroprocaineSmall MoleculeCHRNA10, GRIN3A, HTR3A, SCN10A, SLC6A35
DB01173OrphenadrineSmall MoleculeGRIN1, GRIN2D, GRIN3A, GRIN3B, HRH1, SCN10A, SLC6A27
DB01174PhenobarbitalSmall MoleculeCHRNA4, CHRNA7, GABRA1, GRIA2, GRIK2, GRIN1, GRIN2A, GRIN2B, GRIN2 ......13
DB01221KetamineSmall MoleculeBCHE, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, GRIN3A, HTR1A, HTR1 ......23
DB01520TenocyclidineSmall MoleculeGRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B6
DB01549RolicyclidineSmall MoleculeDRD2, GRIN3A2
DB01708PrasteroneSmall MoleculeAR, ESR1, ESR2, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GA ......33
DB03575PhencyclidineSmall MoleculeGRIN3A, SIGMAR12
DB04896MilnacipranSmall MoleculeGRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, SLC6A2, SLC ......9
DB04926NeramexaneSmall MoleculeGRIN3A1
DB06151AcetylcysteineSmall MoleculeACY1, CHUK, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3A, GSS, IKBKB, SLC ......10
DB06738KetobemidoneSmall MoleculeGRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, OPRD1, OPRK ......10
DB06741GavestinelSmall MoleculeGRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B7
DB09409Magnesium acetate tetrahydrateSmall MoleculeGRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B7
DB09481Magnesium carbonateSmall MoleculeGRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B7
DB13146Fluciclovine (18F)Small MoleculeGRIA1, GRIA2, GRIA3, GRIA4, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, ......14